Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Samsung Biologics Extends Collaboration with LigaChem Biosciences for ADC Development
Details : The collaboration will further strengthen LigaChem Biosciences capabilities across all stages of ADC development to treat solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : LCB97
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : $700.0 million
Deal Type : Licensing Agreement
Ono Inks $700M Biobuck Deal to Bag Preclinical LigaChem ADC
Details : Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97, a pre-clinical stage antibody-drug conjugate, for solid tumors.
Product Name : LCB97
Product Type : Large molecule
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : LCB97
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : $700.0 million
Deal Type : Licensing Agreement